2[1]Yu Jo Chua,David Cunningham.Chemotherapy for advanced pancreatic cancer.Best Practice & Research Clinical Gastroenterology,2006,20 (2):327
3[2]Rosenberg,Lawrence.Pancreatic cancer:A review of emerging therapies.J Drugs,2000,59 (5):1071
4[3]F Viret,M Ychou,D Lepille.Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer.Final results of a multicenter randomized phase Ⅱ study.Proc ASCO,2004,23:4118A
5[4]CP Li.A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer.Proc ASCO,2004,23:4144A
6[5]Anna Maria Storniolo.An investigational new drug treatment program for patients with gemcitabine results for over 3000 patients with pancreatic carcinoma.cancer,1999,85 (6):1261
7[6]DH Palmer,DD Stocken,JAC Buckels,et al.A randomized phase Ⅱ trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer:Gemcitabine alone vs.gemcitabine combined with cisplatin.Proc ASCO,2004,23:4215A
8[7]JL Van Laethem,M Polus,R Marechal.Gemcitabine and xaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer:A phase Ⅱ study.Proc ASCO,2004,23:4119A
9[8]Oettle H,Richards D,Ramanathan RK,et al.A phase Ⅲtrial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.J Ann Oncol,2005,16 (10):1639
10[9]Rocha Lima CM,Green MR,Rotche R,et al.Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor responserate.J Clin Oncol,2004,22 (18):3776
